Working... Menu

LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00906048
Recruitment Status : Terminated (lack of recruitment)
First Posted : May 21, 2009
Last Update Posted : February 7, 2011
Information provided by:

Brief Summary:

The primary objective is: to assess the microbiological success of the combination of levofloxacin and rifampicin, administered for 32 to 37 days, as oral replacement therapy of an empirical antibiotic therapy of a maximum of 5 to 10 days given intravenously, in the treatment of OsteoArticular Prosthetic Infections (OAPI), with a two-stage revision of the prosthesis.

The secondary endpoints are:

  • To assess the rate of clinical failure 12 months after the reimplantation of the prosthesis.
  • To assess the joint mobility function score 12 months after the reimplantation of the prosthesis.
  • To assess the safety of the combination of levofloxacin and rifampicin.
  • To investigate prognostic factors for success after the end of treatment and at 12 months after the reimplantation of the prosthesis.

Condition or disease Intervention/treatment Phase
Infection Drug: Levofloxacin (HR355) and Rifampicin Therapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A National, Multicenter, Non-comparative Study Evaluating the Efficacy of the Combination of Levofloxacin (500 mg) and Rifampicin (600 or 900 mg Depending on Weight) Administered Once Daily by Oral Route, as Replacement of Empirical Antibiotic Therapy Given Intravenously With a Total Duration of 6 Weeks of the Antibiotic Therapy, in the Treatment of OsteoArticular Prosthetic Infections (OAPI), With a Two-stage Revision of the Prosthesis.
Study Start Date : April 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Levofloxacin and Rifampicin
Drug: Levofloxacin (HR355) and Rifampicin Therapy

Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day

Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin

Primary Outcome Measures :
  1. Microbiological success defined as the percentage of patients with negative peri-operative bacteriological samples and the absence of clinical, biological or radiological signs of infection. [ Time Frame: During the reimplantation of the new prosthesis i.e. 15 days to 3 months after the end of treatment ]

Secondary Outcome Measures :
  1. Clinical failure [ Time Frame: 12 months after reimplantation of the prosthesis ]
  2. Joint mobility function score [ Time Frame: 12 months after reimplantation of the prosthesis ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Osteoarticular prosthetic bacterial infection (hip or knee)
  • Documented microbiological infection due to Staphylococcus aureus and/or coagulase-negative staphylococci, susceptible to fluoroquinolones and to rifampicin with:

    • For Staphylococcus aureus, a minimum of 2 positive perioperative samples is required.
    • For the coagulase-negative staphylococci, a minimum of 3 positive perioperative samples is required. In the event of combination, there is a minimum of 2 positive perioperative samples for Staphylococcus aureus and a minimum of 3 positive perioperative samples for coagulase-negative staphylococci.
  • Two-stage surgical management with: during the first operative stage: removal of the prosthesis, large debridement, implantation or not of a spacer during the second operative stage: implantation of a new cemented prosthesis or not (If possible, without antibiotics as recommended by Sofcot (25), otherwise containing gentamicin).
  • Negative urine pregnancy test for females of child-bearing age.
  • A barrier contraception method throughout the duration of treatment and for the 4 weeks following the discontinuation of rifampicin for females of child-bearing age.

Exclusion criteria:

  • Osteoarticular prosthetic infection at more than one site.
  • Osteoarticular prosthetic infection without bacteriological documentation.
  • Infection due to staphylococci that are not susceptible to fluoroquinolones or rifampicin.
  • Infection not due to staphylococci.
  • Absence of surgical management.
  • More than 2 surgical repeats due to infection at the infected site.
  • Renal impairment with creatinine clearance < 50 ml/min.
  • Hepatic impairment.
  • Hypersensitivity to levofloxacin, to a product in the quinolone class, to rifamycins or to the excipients of the study products.
  • A history of tendinopathy associated with a fluoroquinolone.
  • Glucose-6-phosphate dehydrogenase deficiency.
  • History of convulsions or epilepsy predisposing factors for the occurrence of convulsions.
  • Porphyria.
  • Combination use with protease inhibitors or with delavirdine or nevirapine.
  • Estrogen-progestin and progestin contraceptives.
  • Patient over 65 years of age and who has received corticosteroids.
  • Breast-feeding female.
  • Pregnant female or female who is likely to become pregnant.
  • HIV infection.
  • Inflammatory rheumatism.
  • Treatment with immunosuppressive agents, cardiovascular, neurological or endocrine disease, or other medically significant disease (cancer, etc.) making the conduct of the protocol or the interpretation of the results of the trial difficult.
  • A history of abuse of medicinal products or of alcohol.
  • A patient who may receive treatments that are not authorized by the protocol during the trial.
  • Treatment with another product undergoing pharmaceutical development during the 4 weeks prior to inclusion in the trial.
  • Patient participating in another trial.
  • Patient who is allergic to gentamicin, in the event of implantation of a spacer or of cement with gentamicin.
  • Mental condition making the patient incapable of understanding the nature, objectives and possible consequences of the trial.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00906048

Layout table for location information
Sanofi-Aventis Administrative Office
Paris, France
Sponsors and Collaborators
Layout table for investigator information
Study Director: Nathalie Billon sanofi-aventis administrative office

Layout table for additonal information
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00906048     History of Changes
Other Study ID Numbers: LEVOF_L_03815
First Posted: May 21, 2009    Key Record Dates
Last Update Posted: February 7, 2011
Last Verified: February 2011

Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Antibiotics, Antitubercular
Antitubercular Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers